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Alveolar epithelial type II (ATII) cells are small, cuboidal cells that
constitute60% of the pulmonary alveolar epithelium. These cells
are crucial for repair of the injured alveolus by differentiating into
alveolar epithelial type I cells. ATII cells derived from human ES
(hES) cells are a promising source of cells that could be used
therapeutically to treat distal lung diseases. We have developed a
reliable transfection and culture procedure, which facilitates, via
genetic selection, the differentiation of hES cells into an essentially
pure (>99%) population of ATII cells (hES-ATII). Purity, as well as
biological features and morphological characteristics of normal
ATII cells, was demonstrated for the hES-ATII cells, including
lamellar body formation, expression of surfactant proteins A, B,
and C, -1-antitrypsin, and the cystic fibrosis transmembrane
conductance receptor, as well as the synthesis and secretion of
complement proteins C3 and C5. Collectively, these data document
the successful generation of a pure population of ATII cells derived
from hES cells, providing a practical source of ATII cells to explore
in disease models their potential in the regeneration and repair of
the injured alveolus and in the therapeutic treatment of genetic
diseases affecting the lung.
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The alveolar epithelium covers 99% of the internal surfacearea of the lung and is composed of two major cell types, the
alveolar type I (ATI) cell and the alveolar type II (ATII) cell.
ATI cells are large flat cells through which exchange of CO2/O2
takes place. They cover 95% of the alveolar surface and
comprise 40% of the alveolar epithelium and 8% of the
peripheral lung cells. In contrast, ATII cells are small, cuboidal
cells that cover 5% of the alveolar surface and comprise 60%
of the alveolar epithelium and 15% of the peripheral lung cells.
They are characterized by the unique ability to synthesize and
secrete surfactant protein C (SPC) and by the distinct morpho-
logical appearance of inclusion bodies, known as lamellar bodies.
Important functions of ATII cells are (i) to synthesize, store, and
secrete surfactant, which reduces surface tension, preventing
collapse of the alveolus; (ii) to transport ions from the alveolar
fluid into the interstitium, thereby minimizing alveolar fluid and
maximizing gas exchange; (iii) to serve as progenitor cells for
ATI cells, which is particularly important during reepithelializa-
tion of the alveolus after lung injury; and (iv) to provide
pulmonary host defense by synthesizing and secreting several
complement proteins including C3 and C5 (1–3) as well as
numerous cytokines and interleukins that modulate lymphocyte,
macrophage, and neutrophil functions (4). Severe pulmonary
diseases can be caused by deficiencies or genetic mutations in
proteins synthesized by ATII cells that are important in main-
taining normal lung homeostasis. For example, complete defi-
ciency of surfactant protein B (SPB) is caused by genetic
mutations in the SPB gene. This deficiency results in impaired
pulmonary surfactant composition and function and is a major
cause of fatal neonatal respiratory disease (5, 6). In addition,
ATII cells synthesize and secrete the serine protease inhibitor
-1-antitrypsin (-1AT), which also plays a key role in alveolar
homeostasis by regulating protease imbalance and adjusting
fluid clearance (7, 8), the importance of which is supported by
the association of -1AT deficiency with the development of
pulmonary emphysema (9). Cystic fibrosis is thought to be
primarily a disease of the upper airway and submucosal epithelia
and is caused by mutations in the cystic fibrosis transmembrane
conductance receptor (CFTR) (10). CFTR is an important
regulator of Cl and liquid transport in the lung (11–14) and is
functionally expressed by human ATII cells, strongly suggesting
a critical role for CFTR in regulating ion and fluid transport in
the lung alveolus in addition to the upper airway (13).
ES cells isolated from the inner cell mass of blastocyst-stage
embryos are undifferentiated, pluripotent cells (15, 16), which
can be induced to differentiate in vitro into a wide range of
different cell types (17–25). The potential clinical use of ES cells
to regenerate or repair damaged tissue has fueled a tremendous
amount of research activity to develop methods that promote the
differentiation of ES cells into specific cell lineages. Because of
its numerous important functions, including its ability to prolif-
erate and differentiate into the easily damaged ATI cell, human
ES (hES) cell-derived ATII (hES-ATII) cells are promising as a
source of cells that could be used therapeutically to treat distal
lung injury as well as pulmonary genetic disorders. Recently
published data demonstrated that ES cells can be differentiated
into ATII cells via embryonic body (EB) formation (26, 27) or
coculture of EBs with pulmonary mesenchyme (28). However,
these procedures were not efficient, generating only a very small
percentage of ES cell-derived ATII cells (29). A mixed popula-
tion of cell derivatives, as those generated in these reports, will
not be suitable for transplantation into the lung. In addition, the
pluripotent cells in the differentiating cultures carry a significant
risk of producing teratomas after transplantation in vivo. There-
fore, a major prerequisite for using ATII cells therapeutically is
to achieve a pure population of hES-ATII cells. Selection
strategies such as those employing protein markers or drug-
resistance genes under the control of cell-specific promoters may
be highly effective in producing a pure culture of ES cell-derived
donor cells (30). The aim of the following study was to achieve
a pure population of hES-ATII cells based on the hypothesis that
hES cells cultured on Matrigel-coated dishes can be efficiently
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differentiated into ATII cells without EB formation and that a
highly pure population of ATII cells can be generated by genetic
selection of hES cells transfected with a SPC promoter/NEOr
fusion gene.
Results
Derivation and Selection of ATII Cells from hES Cell Lines. The
structure of the human SPC promoter-neomycin transgene
(3-hprt-SPCP.NEO) is depicted in Fig. 1. The hES cell line H9.2
was transfected with the linearized transgene as described in
Methods. Of the 1 million hES cells subjected to transfection,
216 survived puromycin selection. Of these, 12 were found to
contain a single copy of the correctly inserted transgene, of which
one (SPCP/NEO.74) was selected for further investigation. To
induce spontaneous differentiation in vitro, H9.2 and SPCP/
NEO.74 cell lines were cultured in six-well extra-low-attachment
plates for 5 days to form EBs. The presence of ATII cells in the
differentiating cultures of both hES cell lines was determined by
RT-PCR specific for SPC RNA. No SPC RNA was detected in
the undifferentiated hES cells (day 0) or in the differentiating
cultures on day 10. SPC RNA was detected in differentiating
cultures of H9.2 and SPCP/NEO.74 hES cells by day 15, with
significant increases of SPC RNA observed in both hES cultures
on day 25 (Fig. 2 Upper Left). The ability of hES cells to directly
differentiate into ATII cells in vitro without EB formation was
examined by culturing the cells on Matrigel-coated plates in
differentiation medium (DM). SPC RNA expression was de-
tected as early as day 10 in both hES cell lines under these culture
conditions (Fig. 2 Upper Right). Therefore, compared with
cultures differentiated via EB formation, ATII cells appeared 5
days earlier in differentiating hES cells cultured on Matrigel-
coated plates. To examine whether hES cell-derived ATII cells
can be enriched by genetic selection, differentiating cultures of
SPCP/NEO.74, with or without EB formation, were subjected to
G418 treatment (20 g/ml). SPC RNA expression was detected
in G418-selected cultures with EB formation on day 10 (Fig. 2
Lower Left) and without EB formation on day 5 (Fig. 2 Lower
Right), but not in nonselected cultures at corresponding time
points. In addition, significantly higher levels of SPC RNA in
G418-selected cells were observed compared with nonselected
cells at the longer time points of differentiation (Fig. 2 Lower).
Collectively, these results indicate that the SPCP/NEO.74 dif-
ferentiating cell cultures can be enriched in ATII cells after
selection with G418 treatment and that hES cell-derived ATII
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Fig. 1. Structure of the SPC promoter-NEO transgene 3-HPRT vector. A
3.8-kb human genomic DNA fragment containing the SPC promoter and 170
bp of noncoding sequence of exon 1 was cloned into the 3-hprt targeting
vector containing the puromycin-resistance gene. The Neor gene was added
downstream of the SPC promoter. The EcoRI site located between the Agouti
and Neor gene was used to linearize the plasmid before transfection.
Fig. 2. Relative RNA levels of SPC in G418-selected and nonselected differentiating hES cells. SPC-specific RT-PCR was performed by using total RNA isolated
from differentiating cultures of hES cell lines H9.2 and SPCP/NEO.74. (Left) Data obtained from differentiating cells subjected to EB formation. (Right) Data
obtained from differentiating cells without EB formation. (Lower) The results from G418-selected SPCP/NEO.74 hES cells. Lanes M, 1-kb DNA ladder. Lanes C, the
SPC-specific RT-PCR positive control using RNA isolated from the ATII cell line A549. The lower blot in each panel shows the 18S-specific RT-PCR, demonstrating
that changes in the amount of SPC-specific 327-bp RT-PCR product was due to corresponding changes in SPC RNA expression. Total days of differentiation at
which the RNA samples were obtained are indicated.
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Flow Cytometry Analysis of SPC Protein Expression. The differenti-
ated hES cell cultures without EB formation (days 10 and 15)
were examined for ATII-specific SPC protein expression by flow
cytometry. These studies revealed low level SPC protein expres-
sion in the differentiated culture of H9.2 cells on day 10, which
did not increase on prolonged culture (15 days) (Fig. 3). Similar
SPC protein levels were observed in the differentiated cultures
of the SPCP/NEO.74 cell line. In contrast, when genetically
selected by G418 treatment for 10 and 15 days, differentiated
cultures of SPCP/NEO.74 exhibited significantly higher levels of
SPC protein expression (Fig. 3). The levels of SPC protein in the
genetically selected SPCP/NEO.74 cultures were comparable to
that of the human ATII cell line A549.
Immunofluorescent Staining of SPC, Surfactant Protein A (SPA), and
SPB in hES-ATII Cells. The synthesis of SPC is a unique feature of
ATII cells and is commonly used to identify these cells from
other lung parenchymal cells. Undifferentiated hES cells, H9.2
and SPCP/NEO.74, did not stain positive for SPC. As expected,
however, the G418-selected hES-ATII cells, as well as the A549
cells, displayed intense staining with rabbit anti-human SPC
antibody (Fig. 4). At higher magnification (630), SPC-specific
staining can be seen throughout the cytoplasm, with more
intense staining observed in the perinuclear region, suggesting
the presence of SPC in the Golgi/ER compartments. In addition
to SPC, the hES-ATII and A549 cells were shown to express SPA
and SPB (Fig. 4).
Percentage of hES-ATII Cells in Differentiated Cell Cultures. SPC
staining was used to determine the percentage of ATII cells in
differentiated hES cell cultures. SPC-positive staining was dis-
played in only 11.2% of the differentiated hES cells in the
nonselected H9.2 ES cell culture (Table 1). Similar results were
observed in the nonselected SPCP/NEO.74 cell culture (12.6%).
In stark contrast, 99.6% of cells in the G418-selected differen-
tiated culture of SPCP/NEO.74 cells expressed SPC protein,
indicating that G418 selection of the transfected hES cells
produced an essentially pure culture of ATII cells.
Identification of Lamellar Bodies in hES-ATII Cells by Transmission
Electron Microscopy and Papanicolaous Staining. Lamellar bodies
are intracellular organelles that contain pulmonary surfactant
proteins and lipids. The presence of lamellar bodies is a criterion
traditionally used for the identification of ATII cells. To deter-
mine whether the hES-ATII cells contained these intracellular
organelles, G418-selected hES-ATII cells were examined by
transmission electron microscopy. The hES-ATII cells exhibited
ultrastructural features characteristic of human type II cells,
including cytoplasmic lamellar bodies as seen in A549 cells (31)
(Fig. 5). Supporting the electron microscopy data, lamellar
bodies were also detected in the differentiated hES cultures by
Papanicolaous staining, which is another procedure routinely
used for the identification of lamellar bodies (32).
Expression of Human CFTR, -1AT, and Complement Proteins C3 and
C5.Because, ATII cells express CFTR and -1AT in vivo and play
an important role in alveolar homeostasis, the hES-ATII cells
Fig. 3. Flow cytometry examining SPC expression in G418-selected and
nonselected cultures of differentiating hES cells. hES cell lines H9.2 and
SPCP/NEO.74 were induced to differentiate by culturing on Matrigel-coated
plates with DM for 10 days (Left) or 15 days (Right). The differentiated cells
were dissociated and immunostained by rabbit anti-human SPC antibody for
flow cytometry analysis as described in Methods. Results using the SPC anti-
body are depicted by solid lines, and nonimmune rabbit serum controls are
illustrated by dashed lines.
Fig. 4. Immunofluorescence of SPA, SPB, and SPC in SPCP/NEO.74-derived
ATII cells. The hES cell-derived ATII cells generated by G418 selection from the
SPCP/NEO.74 cell line and A549 cells were immunostained by rabbit anti-
human SPA, SPB, and SPC antibodies (red) and nuclear-counterstained with
DAPI (blue). (Magnification: 400.)
Table 1. Relative ATII cell content in nonselected and











H9.2  58 442 11.2
SPC/NEO.74  63 437 12.6
SPC/NEO.74  498 2 99.6














were examined for expression of CFTR and -1AT RNA by
RT-PCR. As anticipated, specific RNA transcripts of CFTR and
-1AT were observed in the hES-ATII cells and A549 cells, but
not in the starting undifferentiated hES cell lines (Fig. 6). ATII
cells are thought to be a major cell source of local production of
complement proteins in the lung. Therefore, we also tested
whether hES-ATII cells have the ability to synthesize and secrete
C3 and C5, major components of the complement system.
ELISA measurements of the cell culture supernatants indicated
that early differentiated ATII cells (day 10) synthesized and
secreted C3 at a rate of 33  3 ng/mg every 24 h, which was
comparable to that produced by the human ATII cell line A549
(data not shown). Similar levels of C3 were also observed on day
12 and day 15 (Fig. 6 Upper Right). C5 was also detected but only
in the day 15 cultures (1.6 ng/mg every 24 h) (Fig. 6 Lower Right).
The amount of C5 produced by the hES-ATII cells was similar
to the quantity of C5 produced by primary cultures of rat and
human ATII cells (1).
Discussion
Lung injury due to chronic pulmonary diseases, such as chronic
obstructive pulmonary disease and asthma, and inherited genetic
disorders, such as cystic fibrosis and 1-AT deficiency are
leading causes of morbidity and mortality worldwide. Cystic
fibrosis and 1-AT deficiency are two of the most common
inherited genetic defects affecting Caucasians. In addition, SPB
deficiency is a major cause of respiratory disease and fatality in
neonates. All three of these diseases are caused by single-gene
defects and therefore have been logical candidates for gene
therapy. However, efficient vector delivery and sufficient trans-
gene expression needed for therapeutic benefit have remained
elusive. Recent research advances indicate that gene delivery via
transplantation of cells derived from human stem cells may
provide an attractive alternative to viral or liposome vector-
based gene therapies. Moreover, transplantation of cells derived
from human stem cells may prove ideal for the repair and
regeneration of injured lung tissue.
Because of its ability to proliferate as well as to differentiate
into ATI cells, the ATII cell is an excellent choice of lung cell for
possible therapeutic use in gene delivery and repair of the
alveolus. However, the generation of hES-ATII cells in sufficient
purity and number for transplantation purposes has proven
difficult. Until now, only one laboratory has reported the
differentiation of ATII cells from hES cells (27). In this report
multiple steps were used to derive ATII cells through EB
formation. This approach required prolonged time periods to
develop the endoderm from which the ATII cells are derived;
however, only a scarce number of ATII cells were produced.
Because the direct differentiation of hES cells into ATII cells
had yet to be investigated, we examined the possibility of
differentiating hES cells to ATII cells without EB formation. As
Fig. 5. Transmission electron micrographs of A549 and hES-ATII cells. (A)
A549 cells with characteristic cytoplasmic electron-dense and loose lamellar
bodies. (B and C) Magnified views of regions * and **, respectively, more
clearly showing the structure of the lamellar bodies. (D) hES cell-derived ATII
cells showing similar lamellar bodies and other morphological characteristics
as the A549 cells. (E and F) Magnified views of regions * and ** in D,
respectively, showing clear lamellar structures. (Scale bars: 5m inAandDand
0.5 m in B, C, E, and F.)
Fig. 6. Expression of CFTR, -1AT, and the complement proteins C3 and C5 by hES-ATII cells. Total RNA isolated from hES cell-derived ATII cells was used to
examine CFTR and -1AT expression by RT-PCR as described in Methods. The RNA expression levels of CFTR and -1AT in hES cell-derived ATII cells were
comparable with that in A549 cells but were not detectable in the undifferentiated hES cell lines H9.2 and SPCP/NEO.74 (Left). C3 and C5 proteins produced by
hES cell-derived ATII cells were determined by ELISA as described in Methods. (Upper Right) Bar graph depicting C3 protein levels from the hES cell-derived ATII
cultures on days 10, 12, and 15. The numerical values on these days were 33  3, 32  3, and 35  3 ng/mg total protein per 24 h, respectively. (Lower Right)
Bar graph depicting C5 protein levels from the hES cell-derived ATII cultures. C5 protein in the hES cell-derived ATII cells was measurable in the day-15 culture
(1.6  0.1 ng/mg total protein per 24 h).
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documented by RT-PCR, flow cytometric analysis, and immu-
nostaining, hES cells cultured on Matrigel-coated dishes did in
fact differentiate directly into ATII cells without EB formation.
In addition, SPC expression indicating the presence of ATII cells
in the differentiating hES cell cultures occurred 5 days sooner in
the absence of EB formation. Moreover, 11.2% of differentiated
cells cultured on the Matrigel-coated dishes were determined to
express SPC protein on day 15 compared with 2.8% on day 33,
when the EB formation approach was used (33). Collectively,
these results suggest that the components of Matrigel, such as
laminin and collagen IV, may not only efficiently maintain the
biological characteristics of ATII cells but also encourage dif-
ferentiation of hES cells to ATII cells.
The use of ES cells as a source of transplantable cells in the
lung alveolus will require the generation of significant quantities
of highly pure ATII cells. To achieve this goal, we chose to
genetically modify hES cells so that resulting differentiated ATII
cells could be enriched through antibiotic selection. Our ap-
proach was to establish a stable transfected hES cell line
containing a single copy of the human SPC promoter-Neor
fusion gene. When subjected to differentiation in vitro, it was
hypothesized that ATII cells derived from this genetically mod-
ified hES cell line (SPCP/NEO.74) would express the Neor gene
and would therefore survive G418 antibiotic selection, whereas,
all of the other differentiated cell lineages as well as the
pluripotent cells would be eliminated by G418 selection. Immu-
nocytochemical and flow cytometric analysis of the surviving
G418-selected cells supported this hypothesis, indicating that
this genetic selection approach resulted in an enrichment of
hES-ATII cells to 99% when cultured on Matrigel-coated
plates. Our protocol reproducibly produced from each 10-cm
culture dish 106 essentially pure ATII cells within 15 days of
differentiation. These differentiated ATII cells survive for at
least 2 days in culture in the absence of G418 and will provide
in a timely manner sufficient numbers of pure ATII cells for
future transplantation investigations.
Ultrastructural examination by transmission electron micros-
copy and Papanicolaous staining demonstrated that the hES-
ATII cells are morphologically normal and exhibit typical la-
mellar bodies, which are a characteristic hallmark of primary
ATII cells. The hES-ATII cells were shown to exhibit normal
important biological functions, such as the synthesis of SPA,
SPB, and SPC. Moreover, these cells expressed RNA specific for
CFTR and -1AT, suggesting that they may have therapeutic
value in the treatment of patients with cystic fibrosis or -1AT
deficiency. The hES-ATII cells also synthesized and secreted
complement proteins C3 and C5, which are important in inflam-
mation and host defense in the lung. Activation of C3 and C5
produces the potent complement anaphylatoxins, C3a and C5a.
Recent reports indicate that C3a and C5a have novel and
important roles in tissue regeneration (34), and neurogenesis
(35). These findings suggest that C3 and C5 synthesized and
secreted by ATII cells are not only important in mediating
pulmonary inflammation and host defense but could also play
critical biological roles in alveolus regeneration and repair. In
conclusion, this study provides a description of a unique single-
step procedure that can be used reliably to drive the differen-
tiation of hES cells into a highly pure population of ATII cells.
These hES-ATII cells are morphologically normal, express the
characteristic SPA, SPB, and SPC, CFTR and -1AT RNA, as
well as synthesize and secrete complement proteins C3 and C5,
and thereby provide a practical transplantable source of ATII
cells that could be used in the future to repair damaged lung
alveolus as well as to treat genetic diseases that affect the lung.
Methods
Human SPC Promoter-Neomycin Vector. A 3.8-kb fragment of hu-
man genomic DNA containing the human SPC promoter and
170 bp of noncoding sequence of exon 1 (36) was cloned into the
AscI site of the 3-hprt insertion targeting vector (37) (a gift from
Allan Bradley, The Wellcome Trust Sanger Institute, Cam-
bridge, U.K.). The Neor cDNA-poly(A) fragment was subcloned
into an engineered NdeI restriction site downstream of the SPC
promoter. The resulting vector (3-hprt-SPCP.NEO) is depicted
in Fig. 1 and was linearized by EcoRI before transfection.
Transfection and Selection of hES Cells. The National Institutes of
Health-approved hES cell line H9.2 (passages 45–65) (WiCell,
Madison, WI) was used throughout this study. Undifferentiated
hES cells were cultured on mitotically inactivated mouse em-
bryonic fibroblasts in six-well plates with hES cell culture
medium containing 80% DMEM/F12, 20% knockout serum
replacement (Gibco Invitrogen, Carlsbad, CA), 1% nonessential
amino acid, 1 mM L-glutamine (Chemicon, Temecula, CA), 0.1
mM 2-mercaptoethanol, and 4 ng/ml basic FGF (Gibco Invitro-
gen). The hES cells from one six-well plate were resuspended in
100 l of supplemented Mouse ES Cell Nucleofector Solution,
mixed with 5 g of the linearized 3hprt-SPCP.NEO vector, and
transfected by using the cell Nucleofector II (Amaxa, Gaithers-
burg, MD). The hES cells were then plated on Matrigel-coated
10-cm plates with mouse embryonic fibroblast conditioned hES
cell medium (MEF-CM) (38). The 3-hprt-SPCP.NEO trans-
fected hES cells were selected in the presence of 0.25 g/ml
puromycin (Sigma, St. Louis, MO) for 14 days. Surviving hES
clones were examined for the Neor gene by PCR analysis, and a
positive clone (SPCP/Neo.74) containing a single copy of the
transgene was selected for further analysis.
In Vitro Differentiation and Selection of hES Cell-Derived ATII Cells.To
induce spontaneous differentiation via EB formation, collage-
nase IV dissociated hES cells were plated on six-well ultra-low-
attachment plates in hES cell medium. On day 2, the resultant
EBs were collected, washed, and cultured on fresh six-well
ultra-low-attachment plates with DM, composed of 80% knock-
out DMEM (Gibco Invitrogen), 20% FBS, 1% nonessential
amino acid, 1 mM L-glutamine, 100 g/ml penicillin, and 100
g/ml streptomycin. On day 6, the EBs were collected and
seeded on gelatin-coated six-well culture plates in DM (15 EBs
per well) and allowed to expand. Selection of hES cell-derived
ATII cells was started on day 6 by adding 20g/ml G418 (Gibco).
To promote the differentiation without EB formation, the
collagenase IV dissociated hES cells were seeded on Matrigel-
coated six-well plates with MEF-CM (day 0). On day 1, the
medium was replaced by DM with or without G418 (20 g/ml).
RT-PCR. Total RNA was isolated from the hES cultures by using
RNA Bee (Tel-Test, Friendswood, TX) following the manufac-
turer’s protocol. The following primer pairs were used in the
RT-PCRs, employing 0.5 g of total RNA and the OneStep
RT-PCR kit (Qiagen, Valencia, CA): (i) SPC forward (5-TGG
TCC TCA TCG TCG TGG TGA TTG-3) and SPC reverse
(5-CCT GCA GAG AGC ATT CCA TCT GGA AG-3), (ii)
CFTR forward (5-GGA GGG ATT TGG GGA ATT ATT
TGA GAA AGC-3) and CFTR reverse (5-CTA TAT TCA
TCATAGGAAACACCAAAGATG-3), (iii) 1-AT forward
(5-TGA CAC TCA CGA TGA AAT CCT GGA G-3) and
1-AT reverse (5-CCT TGA GTA CCC TTC TCC ACG TAA
TC-3), and (iv) 18S forward (5-TAA CGA ACG AGA CTC
TGG CAT-3) and 18S reverse (5-CGG ACA TCT AAG GGC
ATC ACA G-3).
Immunofluorescence and Flow Cytometry. Differentiated hES cells
were dissociated into single-cell suspensions by incubation with
0.25% trypsin for 2 min. The dissociated cells were resuspended
(0.3  106 cells) in 250 l of fixation/permeabilization solution
(Cytofix/Cytoperm kit; BD Biosciences, Franklin Lakes, NJ),














kept on ice for 20 min, and washed twice with Perm/Wash buffer.
After blocking with 10% goat serum in 300 l Perm/Wash buffer
for 45 min on ice, the cells were incubated with rabbit anti-
human SPC antibody (1:200 dilution; Chemicon) in the block
solution for 45 min on ice. The cells were resuspended in 350 l
of Perm/Wash buffer after incubation with goat anti-rabbit IgG
conjugated by R-Phycoerythrin (Sigma, St. Louis, MO) for 45
min on ice, washed twice, and analyzed by flow cytometry. For
immunofluorescent staining, the differentiated hES cells, with
or without G418 selection, were dissociated and seeded on
polyD-lysine-coated coverslips, cultured for 24 h, and stained
with the rabbit anti-human SPC antibody following the manu-
facturer’s directions. The SPC-positive cells were visualized with
Alexa Fluor 546 conjugated goat anti-rabbit IgG (1:1,000;
Molecular Probes, Eugene, OR) with DAPI counterstaining.
The number of SPC-positive cells was counted per 500 cells
based on the DAPI staining on each slide. This procedure was
also used for immunostaining of SPA and SPB using rabbit
anti-human SPA and anti-human proSPB (1:1,000; Chemicon).
Electron Microscopy. The G418-selected hES cell-derived ATII
cells and A549 cells were trypsinized and fixed (2 h) in suspen-
sion with 0.1 M sodium cacodylate buffer containing 2.5%
glutaraldehyde and then postfixed in 1% tannic acid (5 min)
followed by 1% osmium tetroxide (1 h) and then aqueous uranyl
acetate (1 h). Samples were subsequently dehydrated in a graded
ethanol series and embedded in Araldite resin, and ultrathin
serial sections (100 nm) were obtained by using an ultramic-
rotome (RMC 7000; RMC, Tucson, AZ) equipped with a
diamond knife. Sections were stained with uranyl acetate and
lead citrate before photographing with a JEOL 200CX electron
microscope.
ELISA Analysis. Cultures (4, 9, 11, or 14 days) of differentiating
hES cell-derived ATII cells and A549 cells were switched to
DMEM with 15% FBS and incubated for 24 h, and 100 l
samples of each culture were added to 96-well plates that had
been coated with either anti-human C3c or anti-human C5
antibodies (2 g/ml; Quidel, La Jolla, CA). After incubation at
room temperature for 2 h, the plates were exhaustively washed,
incubated for 2 h with the primary goat anti-human C3 and
anti-human C5 antibodies (Complement Technology, Tyler,
TX), washed, and incubated for 1 h with alkaline phosphatase-
conjugated rabbit anti-goat IgG (Sigma). Samples were devel-
oped by using the Alkaline Phosphatase Yellow Liquid Substrate
System (Sigma). Results were normalized based on total cell
protein content by lysis of the cells with 50 mM TrisHCl (pH
7.5), 150 mM NaCl, 1.25 mM protease inhibitor (Sigma), and
0.2% SDS. Protein concentrations were determined by using a
protein assay kit (catalog no. 500-0111; Bio-Rad, Hercules, CA).
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